Human liver-specific nanocarrier in a novel mouse xenograft model bearing noncancerous human liver tissue

European Surgical Research

Volumn 46, Issue 2, 2011, Pages 65-72

  Matsuura, Yoshifumi ^a   Yagi, Hiroshi ^a   Matsuda, Sachiko ^a   Itano, Osamu ^a   Aiura, Koichi ^a   Kuroda, Shun'Ichi ^b   Ueda, Masakazu ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Liver; Mouse xenograft model; Nanocarrier

Indexed keywords

GANGLIOSIDE GM1 ANTIBODY; GANGLIOTETRAOSYLCERAMIDE; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FLUORESCENCE; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY CAPSULE; LIVER; LIVER CELL; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; XENOGRAFT;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUORESCEINS; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, ANIMAL; NANOPARTICLES; TRANSPLANTATION, HETEROLOGOUS; VIRAL ENVELOPE PROTEINS;

EID: 78650233704     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322491     Document Type: Article

References (38)

1. Rahman YE, Rosenthal MW, Cerny EA: Intracellular plutonium: removal by liposomeencapsulated chelating agent. Science 1973; 180: 300-302.
2. Wu GY, Wu CH: Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-14624.
3. Hara T, Aramaki Y, Takada S, Koike K, Tsuchiya S: Receptor-mediated transfer of psv2cat DNA to mouse liver cells using asialofetuin-labeled liposomes. Gene Ther 1995; 2: 784-788. (Pubitemid 26043291)
4. Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA: Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-778. (Pubitemid 28103554)
5. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, Bertin SL, Reppen TW, Chu Q, Blokhin AV, Hagstrom JE, Wolff JA: Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007; 104: 12982-12987. (Pubitemid 351737577)
6. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T, Niitsu Y: Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26: 431-442. (Pubitemid 351501817)
7. Barnett BG, Crews CJ, Douglas JT: Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575: 1-14. (Pubitemid 34521771)
8. Buning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M: Receptor targeting of adeno-associated virus vectors. Gene Ther 2003; 10: 1142-1151. (Pubitemid 36896589)
9. Anderson JL, Hope TJ: Intracellular trafficking of retroviral vectors: obstacles and advances. Gene Ther 2005; 12: 1667-1678. (Pubitemid 41679170)
10. Jung J, Matsuzaki T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S: Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release 2008; 126: 255-264.
11. De Bartolo L, Salerno S, Morelli S, Giorno L, Rende M, Memoli B, Procino A, Andreucci VE, Bader A, Drioli E: Long-term maintenance of human hepatocytes in oxygen-permeable membrane bioreactor. Biomaterials 2006; 27: 4794-4803. (Pubitemid 43849982)
12. Kekonen EM, Jauhonen VP, Hassinen IE: Oxygen and substrate dependence of hepatic cellular respiration: sinusoidal oxygen gradient and effects of ethanol in isolated perfused liver and hepatocytes. J Cell Physiol 1987; 133: 119-126. (Pubitemid 18022454)
13. Uygun BE, Soto-Gutierrez A, Yagi H, Izamis ML, Guzzardi MA, Shulman C, Milwid J, Kobayashi N, Tilles A, Berthiaume F, Hertl M, Nahmias Y, Yarmush ML, Uygun K: Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 2010;16: 814-820.
14. Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R, Ben-Moshe O, Arazi J, Berr S, Neville L, Yuen L, Mansour TS, Gillard J, Eid A, Jurim O, Shouval D, Reisner Y, Galun E: The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology 1999; 29: 553-562. (Pubitemid 29088462)
15. Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA: Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis δ viruses. Nat Med 2000; 6: 327-331. (Pubitemid 30148626)
16. Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, Roy-Chowdhury N, Roy-Chowdhury J: A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in rag-2-deficient mice. Hepatology 2000; 31: 173-181. (Pubitemid 30033704)
17. Gupta S, Bhargava KK, Novikoff PM: Mechanisms of cell engraftment during liver repopulation with hepatocyte transplantation. Semin Liver Dis 1999; 19: 15-26. (Pubitemid 29220828)
18. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G: Morphological and biochemical characterization of a human liver in a UPA-SCID mouse chimera. Hepatology 2005; 41: 847-856. (Pubitemid 40462948)
19. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM: Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933. (Pubitemid 32756430)
20. Azuma H, Paulk N, Ranade A, Dorrell C, Al- Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M: Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/ Il2rg-/- mice. Nat Biotechnol 2007; 25: 903-910. (Pubitemid 47236918)
21. Dandri M, Lutgehetmann M, Volz T, Petersen J: Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 2006; 26: 181-191. (Pubitemid 43668260)
22. Bissig KD, Le TT, Woods NB, Verma IM: Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc Natl Acad Sci USA 2007; 104: 20507-20511.
23. He Z, Zhang H, Zhang X, Xie D, Chen Y, Wangensteen KJ, Ekker SC, Firpo M, Liu C, Xiang D, Zi X, Hui L, Yang G, Ding X, Hu Y, Wang X: Liver xeno-repopulation with human hepatocytes in Fah-/-Rag2-/- mice after pharmacological immunosuppression. Am J Pathol 2010; 177: 1311-1319.
24. Martin-Vilchez S, Sanz-Cameno P, Rodriguez- Munoz Y, Majano PL, Molina-Jimenez F, Lopez-Cabrera M, Moreno-Otero R, Lara- Pezzi E: The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 2008; 47: 1872-1883. (Pubitemid 351945555)
25. Wang M, Ellison CA, Gartner JG, HayGlass KT: Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J Immunol 1998; 160: 1098-1105. (Pubitemid 28093403)
26. Sherwood ER, Lin CY, Tao W, Hartmann CA, Dujon JE, French AJ, Varma TK: Beta 2 microglobulin knockout mice are resistant to lethal intraabdominal sepsis. Am J Respir Crit Care Med 2003; 167: 1641-1649. (Pubitemid 36760677)
27. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K, Kuroda S: Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 2003; 21: 885-890. (Pubitemid 36936193)
28. Iwasaki Y, Ueda M, Yamada T, Kondo A, Seno M, Tanizawa K, Kuroda S, Sakamoto M, Kitajima M: Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther 2007; 14: 74-81. (Pubitemid 44952236)
29. Chung TW, Lee YC, Kim CH: Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18: 1123-1125.
30. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R: Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223.
31. Ohashi K, Waugh JM, Dake MD, Yokoyama T, Kuge H, Nakajima Y, Yamanouchi M, Naka H, Yoshioka A, Kay MA: Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-140. (Pubitemid 40066391)
32. Escribano O, Fernandez-Moreno MD, Pina MJ, Fueyo J, Menor C, Roman ID, Guijarro LG: Pretreatment with FK506 up-regulates insulin receptors in regenerating rat liver. Hepatology 2002; 36: 555-561. (Pubitemid 34977165)
33. Zhou P, Hohm S, Olusanya Y, Hess DA, Nolta J: Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model. Hepatology 2009; 49: 1992-2000.
34. Fujino H, Hiramatsu H, Tsuchiya A, Niwa A, Noma H, Shiota M, Umeda K, Yoshimoto M, Ito M, Heike T, Nakahata T: Human cord blood CD34+ cells develop into hepatocytes in the livers of NOD/SCID/gamma(c)null mice through cell fusion. FASEB J 2007; 21: 3499-3510. (Pubitemid 350075140)
35. Kuroda S, Fujisawa Y, Iino S, Akahane Y, Suzuki H: Induction of protection level of antipre- S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of m (pre-S2 + s) protein particles (a third generation vaccine). Vaccine 1991; 9: 163-169.
36. Gripon P, Cannie I, Urban S: Efficient inhibition of hepatitis b virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622. (Pubitemid 40459108)
37. Le Seyec J, Chouteau P, Cannie I, Guguen- Guillouzo C, Gripon P: Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol 1998; 72: 5573-5578. (Pubitemid 28283341)
38. Le Seyec J, Chouteau P, Cannie I, Guguen- Guillouzo C, Gripon P: Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol 1999; 73: 2052-2057. (Pubitemid 29098108)